Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Agostina Demaría"'
Autor:
Karina A. Pasquevich, Lorena M. Coria, Ana Ceballos, Bianca Mazzitelli, Juan Manuel Rodriguez, Agostina Demaría, Celeste Pueblas Castro, Laura Bruno, Lucas Saposnik, Melina Salvatori, Augusto Varese, Soledad González, Veronica V. González Martínez, Jorge Geffner, Diego Álvarez, Laboratorio Pablo Cassará R&D and CMC for ARVAC CG consortium, Ethel Feleder, Karina Halabe, Pablo E. Perez Lera, Federico Montes de Oca, Julio C. Vega, Mónica Lombardo, Gustavo A. Yerino, Juan Fló, Juliana Cassataro
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Abstract A Gamma Variant RBD-based aluminum hydroxide adjuvanted vaccine called ARVAC CG was selected for a first in human clinical trial. Healthy male and female participants (18-55 years old) with a complete COVID-19-primary vaccine scheme were ass
Externí odkaz:
https://doaj.org/article/63ec204d1afc426d83ae0e3481ec283a
Autor:
Lorena M. Coria, Juan Manuel Rodriguez, Agostina Demaria, Laura A. Bruno, Mayra Rios Medrano, Celeste Pueblas Castro, Eliana F. Castro, Sabrina A. Del Priore, Andres C. Hernando Insua, Ingrid G. Kaufmann, Lucas M. Saposnik, William B. Stone, Lineia Prado, Ulises S. Notaro, Ayelen N. Amweg, Pablo U. Diaz, Martin Avaro, Hugo Ortega, Ana Ceballos, Valeria Krum, Francisco M. Zurvarra, Johanna E. Sidabra, Ignacio Drehe, Jonathan A. Baqué, Mariana Li Causi, Analia V. De Nichilo, Cristian J. Payes, Teresa Southard, Julio C. Vega, Albert J. Auguste, Diego E. Álvarez, Juan M. Flo, Karina A. Pasquevich, Juliana Cassataro
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract In the context of continuous emergence of SARS-CoV-2 variants of concern (VOCs), one strategy to prevent the severe outcomes of COVID-19 is developing safe and effective broad-spectrum vaccines. Here, we present preclinical studies of a RBD
Externí odkaz:
https://doaj.org/article/98c078c53315430d8a5d5706aeabac1e
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 12, Iss 9, p e0006764 (2018)
BACKGROUND:Drugs currently used for the treatment of Chagas' disease, nifurtimox and benznidazole, have a limited effectiveness and toxic side effects. With the aim of finding new therapeutic approaches, in vitro and in vivo anti-Trypanosoma cruzi ac
Externí odkaz:
https://doaj.org/article/dc792500f8bf43569bace1191f52a331